Liposeuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Liposeuticals, Inc. - overview
Established
2012
Location
-, NJ, US
Primary Industry
Pharmaceuticals
About
Based in New Jersey, US, and founded in 2012, Liposeuticals, Inc. , also known as LSI, operates as a specialty pharmaceutical company that manufactures and develops sterile injectable drugs for the treatment of anesthesiology, oncology, and infectious diseases. The company was founded by its CEO, Nian Wu. In June 2017, Liposeuticals, Inc.
raised Series A funding led by Delos Capital. Liposeuticals manufactures and markets sterile injectable drugs for the treatment of ailments like infection, oncology, and anesthesia. LSI offers Sulocence, which is a sugar-lipid polymer-based formulation platform. The company develops intravenous injection products like LSI-203, LSI-204, LSI-209, and more through its pipeline.
Current Investors
Delos Capital Partners
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.liposeuticals.com
Verticals
Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.